Healthcare, HCP & Life Sciences Media Platforms
Nine platforms, five sub-markets, one honest DACH filter: what is actually bookable here and what remains a US model.
Healthcare media follows different rules than normal programmatic. The audience is dual: professionals (HCP) and patients (DTC), with strictly separated permission spaces. Rx advertising to consumers is prohibited in the EU, person-level health attributes are out under Article 9 GDPR, and the US infrastructure of NPI registries and prescription-adjacent data chains simply does not exist here.
That is why the category needs its own map. Five sub-markets, nine platforms, and for each the same question: identity, context, measurement, and what survives in DACH. We claim no condition-based audiences along the way; where US platforms offer them, the table says so as a US model, with legal review as the mandatory step before it.
Five sub-markets, cleanly separated
HCP networks
Verified physician communities and professional portals: reach through membership and clinical context instead of ad IDs.
Doximity, Medscape, Sermo, Doceree
Healthcare DSPs
Programmatic buying with healthcare data models, in the US down to prescriber level.
DeepIntent, PulsePoint
EHR / point-of-care media
Messages in the care context: inside the physician EHR workflow or on screens in practices and waiting rooms.
OptimizeRx, PatientPoint
Data & measurement partners
Not media buying but impact measurement: prescription-adjacent KPIs and audience quality, within the US frame.
Veeva Crossix
DTC healthcare media
Patient-facing environments (health portals, point of care). Tightly regulated in the EU: Rx advertising to consumers is prohibited; OTC and medtech run with conditions.
WebMD environments, PatientPoint (US)
Evaluation criteria
- HCP identity quality: How solid is verification: registry (NPI), membership, login, or mere inference?
- Specialty targeting: Can campaigns steer by specialty, and where does the attribute come from?
- Clinical context: How close to clinical practice does the message appear: news, CME, workflow?
- EHR / workflow access: Are there placements inside the care or prescribing workflow?
- DTC vs HCP support: Does the platform serve professionals, patients or both, and how cleanly separated?
- Measurement and outcomes: Which impact measurement exists, and does it hold outside the US data frame?
- DSP / open-web access: Programmatically buyable or endemic-only via insertion orders?
- Managed service requirements: Is self-serve possible or is a managed contract mandatory?
- US vs EU/DACH availability: Does the data basis even exist outside the US?
- Privacy and compliance notes: Which legal limits apply, and what strictly requires review before booking?
Nine platforms: identity & context
| Platform | Category | HCP identity | Specialty targeting | Clinical context | EHR / workflow | DTC vs HCP |
|---|---|---|---|---|---|---|
| Doximity | HCP network | Very high (verified US physicians, NPI) | Very good | High (newsfeed, clinical content) | No | HCP only |
| Doceree | HCP network | High (NPI, ID resolution) | Good | Medium (publisher network) | Partly (point-of-care partners) | HCP only |
| PulsePoint | Healthcare DSP | High (NPI-based) | Good | Medium (context signals) | No | HCP + DTC |
| DeepIntent | Healthcare DSP | High (NPI + modeling) | Good | Medium | No | HCP + DTC |
| Veeva Crossix | Data & measurement | n/a (measurement data network) | n/a | n/a | No | Measurement for both |
| Medscape | HCP network | High (registered members) | Good | High (CME, clinical news) | No | HCP (DTC via WebMD sibling) |
| Sermo | HCP network | High (verified physician community) | Good | Community context | No | HCP only |
| OptimizeRx | EHR / point of care | Prescriber in the EHR workflow | Via EHR context | Highest (in workflow) | Core of the product | HCP, plus patient messaging |
| PatientPoint | EHR / point of care | Venue-based (practice, no persons) | Via practice specialty | High (point of care) | Adjacent (practice systems) | DTC at point of care + HCP |
Access, measurement & DACH availability
| Platform | Measurement & outcomes | DSP / open web | Managed share | US vs EU/DACH | Privacy & policy | Notes |
|---|---|---|---|---|---|---|
| Doximity | Rx lift studies (US) | No, endemic/direct | Managed, IO-based | US only | US model (NPI), no EU equivalent | The reference for US HCP reach; no data basis for DACH. |
| Doceree | Campaign & script metrics (US) | Yes, programmatic hookup | Self-serve & managed | US-first, EU building out; verify for DACH | ID resolution needs legal review in the EU | The most programmatic HCP option; verify the EU setup before booking. |
| PulsePoint | Rx & clinical measurement (US) | Yes (own DSP) | Self-serve & managed | Primarily US | US data model; Article 9 GDPR blocks the EU transfer | WebMD environment included; DACH assessment on the detail page. |
| DeepIntent | Rx lift, measurement partners (US) | Yes (own DSP) | Primarily managed | Primarily US | US data model; Article 9 GDPR blocks the EU transfer | Data and measurement partnerships; DACH assessment on the detail page. |
| Veeva Crossix | US standard (Rx dynamics, audience quality) | Activation via partners | Enterprise, contract-based | US only | HIPAA frame; the model does not transfer to the EU | Not buying but measurement; the standard in US pharma. |
| Medscape | Engagement & brand; Rx partly (US) | Direct/endemic, partly programmatic | Managed, IO-based | Global, incl. a German edition | Login and consent based; review per campaign | One of the few routes with real DACH HCP reach. |
| Sermo | Survey and brand measurement | No, direct | Managed | Global, incl. EU panels | Membership-based, panel consent | Strong for insights and HCP panels, DACH included. |
| OptimizeRx | Script impact (US) | No | Managed, pharma contracts | US only (US EHR systems) | US health-IT frame | Point of prescribing; structurally not transferable to DACH. |
| PatientPoint | Exposure and reach metrics | Partly (programmatic DOOH) | Managed | US only | Venue-based, no person-level targeting | The venue pattern that also works as an approach in DACH. |
Editorial assessment, last checked July 2026, criteria per ourintegrations methodology. Statements about condition- or prescription-based targeting describe US models; they are no booking promise for DACH and replace no legal review.
Medtech in DACH: the workable route
For medical technology (devices, diagnostics, homecare) the DACH route rarely runs through US HCP platforms. It combines clinical context with area logic: HCP reach through networks with a real EU base and regional planning through area signals such asAreaSignal. The method is documented inAreaSignal methodology and privacy (German). The full procedure from audience planning to QA lives in the playbookMedtech HCP Media Activation.
Measurement without Rx data
US campaigns measure against prescription data; DACH campaigns cannot. What carries here: area holdouts against structurally comparable regions, inquiry and lead KPIs in your own stack, and clean conversion tracking through theconversion APIs. The HCP Campaign Tracking Audit examines exactly this chain, from portal click to CRM.
Which platforms carry your healthcare campaign, and what of it is measurable in DACH?
Why do US healthcare platforms not simply work in DACH?
Because the data basis is missing. US models build on NPI registries and prescription-adjacent data chains that do not exist here, and person-level health attributes are out under Article 9 GDPR anyway. In DACH, membership, venue and area models carry the load.
Can condition-based audiences be booked in DACH?
Not at person level. What remains is clinical context (HCP portals), venue environments (point of care) and area signals such as care-infrastructure density. Every campaign in this category belongs in legal review before booking.
How do medtech companies reach professionals and regions without US data models?
Through a combination: HCP reach via Medscape- or Sermo-type networks, regional planning through area signals such as AreaSignal, and legally reviewed activation routes. Measurement runs on area holdouts instead of Rx data.